Evaluation of drug mechanism and efficacy of a novel anti-angiogenic agent, TTAC-0001, using multi-modality bioimaging in a mouse breast cancer orthotopic model.
| Author | |
|---|---|
| Abstract |
:
Targeting of vascular endothelial growth factor receptors (VEGFRs) has potential anti-angiogenic effects because VEGFR-2 is the major signaling regulator of VEGF/VEGFR pathways. We aimed to elucidate the drug mechanism and anti-tumor efficacy of TTAC-0001, a novel, fully human anti-VEGFR-2/KDR monoclonal antibody, in mouse orthotopic breast cancer model using multi-modal bioimaging. |
| Year of Publication |
:
0
|
| Journal |
:
PloS one
|
| Volume |
:
13
|
| Issue |
:
1
|
| Number of Pages |
:
e0187063
|
| Date Published |
:
2018
|
| URL |
:
http://dx.plos.org/10.1371/journal.pone.0187063
|
| DOI |
:
10.1371/journal.pone.0187063
|
| Short Title |
:
PLoS One
|
| Download citation |
